Medical Device Leader Series: Top In Vitro Diagnostics Companies 2013-2023

March 2013 | 191 pages | ID: MAA46CF906EEN
Visiongain

Abstracts

How to find commercial prospects for leading and rising producers of in vitro diagnostic tests

What does the future hold for companies of the in vitro diagnostics (IVD) industry? Visiongain's new report shows you their prospects to 2023. There you see financial results, trends, opportunities and revenue predictions.

To help you assess the future of that industry and market, our study analyses 18 leading IVD developers and manufacturers. That work also explores associated organisations. There you discover how sales of IVD tests can increase and producers' revenues grow.

That way you discover information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

Discover forecasts and discussions to help you stay ahead in knowledge

You gain IVD revenue forecasts to 2023 for 11 companies, and the overall industry, with historical data, growth rates and market shares. Also, you see qualitative analysis, business outlooks and research and development (R&D). You receive 80 tables and 95 charts.

Our work lets you assess the most lucrative areas of those technologies, seeing opportunities both for makers of pharmaceuticals and of diagnostic medical tests.

That way you can stay ahead in knowledge of the IVD industry and market, benefiting your research, analyses and decisions. Also you investigate companies at the forefront of companion diagnostics and personalised medicine. Assess their futures.

Now, the following sections highlight what you find in our new study.

See prospects for leading US-based developers and manufacturers

Our report gives you profiles, discussions and financial analyses - including revenue forecasts to 2023 - for top US companies:

• Danaher
• Abbott Laboratories
• Johnson & Johnson (J&J)
• Bio-Rad
• Becton Dickinson
• Thermo Fisher Scientific.

Discover what the future holds for those diagnostic medical device companies.

In our study you assess product ranges and outlooks. You view linked organisations too - alliances and other collaborations. You also see further activities and strategies, including mergers and acquisitions (M&A). Also, you explore links with the pharmaceutical industry.

Next, our investigation analyses prominent IVD developers and producers in other regions - Europe and Japan.

What are the outlooks for leading European developers and producers?

Our report shows you developments and revenue forecasts to 2023 for leading diagnostics companies based in Europe:

• Roche
• Siemens
• bioMйrieux.

Our work shows you where sales growth can occur. Many opportunities remain, with high, growing revenues possible from 2013 to 2023. You see where the best prospects exist.

Find prospects for leading diagnostics companies based in Japan

You also see outlooks for top Japanese companies developing and producing IVD tests:

• Sysmex
• Arkray.

There, you assess product portfolios, strategies and revenue predictions to 2023.

Our report shows you competitive dynamics and potentials of that medical diagnostics industry. You see possibilities for advancing technology and raising sales performance.

Also you explore other IVD developers, finding how they shape that diagnostic medical devices industry.

Who are the prominent emerging companies?

Our work assesses other companies progressing in that field. There you discover activities of these emerging players and their associated organisations:

• Dako (Agilent Technologies)
• Genomic Health
• Laboratory Corporation of America (LabCorp)
• Life Technologies
• MDxHealth
• Myriad Genetics
• QIAGEN.

The chapters of our report show outlooks for a wide range of companies, from multinationals to emerging specialists in medical diagnostic testing. That way you discover sales data and underlying trends, seeing what the present and future hold.

Find revenue predictions for the overall world market and its components

Our report also forecasts the overarching IVD market and its main segments. There you see individual forecasted revenues to 2023 for seven world-level submarkets:

• Point-of-care (POC) tests
• Clinical chemistry
• Immunochemistry
• Haematological diagnostics
• Microbiological applications
• Genetic testing agents
• Other products.

That study predicts overall world IVD revenues will reach $81bn in 2017. Those analyses show high growth from 2013 to 2023. In them you discover the sales potential of the world market and find its most promising segments - vital areas to watch.

Progress will occur this decade, with product launches and new market entrants. Our analysis shows large companies and specialty healthcare firms will develop and prosper.

Discover now opportunities and potential revenues for the IVD market and its leading participants - established and rising companies.

Six ways Medical Device Leader Series: Top In Vitro Diagnostics Companies 2013-2023 helps you

To sum up then, our investigation gives you the following knowledge:

• Revenues to 2023 for the overall world market and 7 product subcategories - you discover that industry's prospects, finding the most promising areas for investments and revenues
• Profiles of 18 leading companies - you assess products, strategies, sales results and outlooks, also gaining IVD revenue forecasts to 2023
• Competition and opportunities - you see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business
• Coverage of R&D - you investigate progress in diagnostic research and development, exploring technological and clinical possibilities
• Analysis of what stimulates and restrains that industry and market - you assess challenges and strengths, helping you compete and gain advantages
• Prospects for established competitors and firms seeking to enter the sector - you explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Discover prospects for leading IVD producers by ordering now

Our investigation is for everyone needing analysis of the industry and market for diagnostic kits, theranostics and related medical products. There you find data, trends, opportunities and predictions. Please order our report now.

Contents

1. EXECUTIVE SUMMARY

1.1 Leading In Vitro Diagnostic Companies: Overview of Findings
1.2 Chapter Content for this Study
1.3 Research and Analysis Methods
1.4 Scope of this Report
  1.4.1 Products Considered in this Report

2. AN INTRODUCTION TO IN VITRO DIAGNOSTICS

2.1 The In Vitro Diagnostics Market
  2.1.1 The In Vitro Diagnostics Market in 2011
2.2 What are In Vitro Diagnostic (IVD) Tests?
2.3 Classifying In Vitro Diagnostics
  2.3.1 The US Classification
  2.3.2 The EC (European Commission) Classification
  2.3.3 Regulatory Issues in the IVD Market
    2.3.3.1 Regulation of IVD Tests
    2.3.3.2 Lack of Clarity Can be Costly
2.4 Types of IVD Test
  2.4.1 Point Of Care Diagnostics
  2.4.2 Clinical Chemistry
  2.4.3 Microbiology
    2.4.3.1 Regulatory Differences with IVD Microbiology Tests
  2.4.4 Haematology
  2.4.5 Immunochemistry
  2.4.6 Genetic Testing
2.5 The IVD Market: Overall Revenue Forecast to 2023
  2.5.1 Market Drivers, 2013-2023
  2.5.2 Market Restraints, 2013-2023
  2.5.3 Future of the IVD Industry
2.6 Company Comparison
  2.6.1 Fragmented Market
  2.6.2 IVD Market: Leading Manufacturers in 2011

3. THE LEADING US IN VITRO DIAGNOSTIC COMPANIES, 2013-2023

3.1 Danaher
  3.1.1 Sales and Recent Performance Analysis
  3.1.2 Life Sciences and Diagnostics
  3.1.3 Key Products
  3.1.4 Danaher Manufacturing Capabilities
  3.1.5 Danaher IVD Segment: Strengths and Challenges
  3.1.6 Danaher's Life Sciences and Diagnostics Revenues
    3.1.6.1 IVD Revenue Forecast, 2012-2023
  3.1.7 Recent Mergers and Acquisition (M&A) Activity
3.2 Abbott Laboratories
  3.2.1 Sales and Recent Performance Analysis
  3.2.2 Abbott: Diagnostics Segment
    3.2.2.1 In Vitro Diagnostics Products
  3.2.3 Abbott IVD Segment: Strengths and Challenges
  3.2.4 Abbott Diagnostics Historical Revenues, 2009-2011
  3.2.5 IVD Revenue Forecast, 2012-2023
  3.2.6 Recent M&A Activity and Strategic Collaborations
    3.2.6.1 Collaboration with GSK
    3.2.6.2 Collaboration with Merck
    3.2.6.3 Acquisition of STARLIMS Technologies
    3.2.6.4 Acquisition of Ibis Biosciences, Inc.
  3.2.7 Plans to Separate into Two Publicly Traded Companies
3.3 Johnson & Johnson (J&J)
  3.3.1 Sales and Recent Performance Analysis
  3.3.2 Medical Device and Diagnostics Segment Analysis
  3.3.3 IVD Revenue Forecast, 2012-2023
  3.3.4 Recent M&A Activity and Strategic Collaborations
    3.3.4.1 Diagnostics Centre of Excellence
    3.3.4.2 Collaboration with Tianjin Medical University Cancer Institute and Hospital
    3.3.4.3 Partnership with Massachusetts General Hospital
    3.3.4.4 Partnership with Biocartis
3.4 Bio-Rad
  3.4.1 Sales and Recent Performance Analysis
  3.4.2 Clinical Diagnostics
    3.4.2.1 In Vitro Diagnostics
  3.4.3 IVD Revenue 2011
  3.4.4 IVD Revenue Forecast, 2012-2023
  3.4.5 Recent M&A Activity and Strategic Collaborations
  3.4.6 Potential Bio-Rad Labs Takeover Seen in Near-Term
3.5 Becton Dickinson
  3.5.1 Global Presence
  3.5.2 Distribution
  3.5.3 R&D
  3.5.4 Sales and Recent Performance Analysis
    3.5.4.1 Historical Sales Performance Analysis
  3.5.5 BD Diagnostics Revenue
  3.5.6 IVD Revenue Forecast, 2012-2023
  3.5.7 Recent M&A Activity and Strategic Collaborations
3.6 Thermo Fisher Scientific
  3.6.1 Historical Sales and Recent Performance Analysis
  3.6.2 Clinical Diagnostics
  3.6.3 Key Products
  3.6.4 Thermo Fisher's Manufacturing Capabilities
  3.6.5 Thermo Fisher's Diagnostics Revenues
  3.6.6 IVD Revenue Forecast 2012-2023
  3.6.7 Recent Mergers and Acquisition Activity
    3.6.7.1 Acquisition of Dionex and Phadia

4. THE LEADING EUROPEAN IN VITRO DIAGNOSTIC COMPANIES, 2013-2023

4.1 Roche
  4.1.1 Global Presence
  4.1.2 Sales and Recent Performance Analysis
  4.1.3 Roche Diagnostics
  4.1.4 R&D Capabilities
  4.1.5 Growing Portfolio of Diagnostic Products
    4.1.5.1 Exploring Strategies in the Neurological Sector
  4.1.6 IVD Revenue Forecast 2012-2023
  4.1.7 Recent M&A Activity and Strategic Collaborations
    4.1.7.1 Roche Offers to Acquire Illumina to Strengthen its Leading Position in Diagnostics
4.2 Siemens
  4.2.1 Sales and Recent Performance, 2011
  4.2.2 Siemens Healthcare
    4.2.2.1 Siemens Diagnostics
    4.2.2.2 Outperforming the Market
    4.2.2.3 In Vitro Diagnostics
  4.2.3 IVD Revenue Forecast 2012-2023
  4.2.4 Recent M&A Activity and Strategic Collaborations
    4.2.4.1 Partnership with ViiV Healthcare
    4.2.4.2 Partnership with Tocagen
4.3 bioMйrieux
  4.3.1 Sales and Recent Performance, 2011
  4.3.2 IVD Revenue Forecast, 2012-2023
  4.3.3 Recent M&A Activity and Strategic Collaborations
    4.3.3.1 Partnership with GSK
    4.3.3.2 Partnership with Ipsen
    4.3.3.3 Partnership with Institute Merieux and Institute Pasteur
    4.3.3.4 Collaboration with Hospices Civils de Lyon
    4.3.3.5 Acquisition of ARGENE
    4.3.3.6 Equity Interest in Knome

5. THE LEADING JAPANESE IN VITRO DIAGNOSTIC COMPANIES, 2013-2023

5.1 Sysmex
  5.1.1 Global Presence and Distribution
  5.1.2 Sales and Recent Performance Analysis
  5.1.3 Sysmex Diagnostics
  5.1.4 IVD Revenue Forecast 2012-2023
  5.1.5 Recent M&A Activity and Strategic Collaborations
    5.1.5.1 Acquisition of Katakura's Research Institute of Biological Science
    5.1.5.2 Collaboration with IDEXX Labs to Expand into Animal Diagnostics
5.2 Arkray
  5.2.1 Global Presence
  5.2.2 R&D
  5.2.3 IVD Product Portfolio
  5.2.4 Sales and Recent Performance Analysis
  5.2.5 IVD Revenue Forecast 2012-2023

6. EMERGING IN VITRO DIAGNOSTIC COMPANIES, 2013

6.1 Pipeline and Other Companies: An Overview, 2013
6.2 Other Prominent In Vitro Diagnostic Players
6.3 Dako (Agilent Technologies)
  6.3.1 Sales and Recent Performance Analysis
  6.3.2 In Vitro Diagnostics
  6.3.3 M&A Activity and Other Key Developments
6.4 Genomic Health
  6.4.1 Sales and Recent Performance Analysis, 2011
  6.4.2 R&D Capabilities
    6.4.2.1 TAILORx Clinical Trial
    6.4.2.2 RxPonder Trial
    6.4.2.3 Partnership with Oncomed
6.5 Laboratory Corporation of America (LabCorp)
  6.5.1 Sales and Recent Performance Analysis
  6.5.2 In Vitro Diagnostics
  6.5.3 Recent M&A Activity and Other Key Developments
    6.5.3.1 Agreement with Medco Health Sciences
    6.5.3.2 Acquisition of Monogram Biosciences
    6.5.3.3 Non-Exclusive License Agreement with Merck
    6.5.3.4 Acquisition of Genzyme Genetics
    6.5.3.5 Partnership with ARCA Biopharma
6.6 Life Technologies
  6.6.1 Sales and Recent Performance Analysis
  6.6.2 In Vitro Diagnostics
  6.6.3 M&A Activity and Recent Diagnostics Partnerships and Agreements
    6.6.3.1 Acquisition of Navigenics
    6.6.3.2 Partnership with Bristol-Myers Squibb
    6.6.3.3 Acquisition of Compendia Bioscience
    6.6.3.4 Partnership with GSK
6.7 MDxHealth
  6.7.1 Sales and Recent Performance Analysis, 2011
  6.7.2 R&D Capabilities
  6.7.3 In Vitro Diagnostics
    6.7.3.1 PharmacoMDx
    6.7.3.2 PredictMDx for Brain Cancer
    6.7.3.3 PredictMDx for Colon Cancer
    6.7.3.4 Partnership with GSK
6.8 Myriad Genetics
  6.8.1 Sales and Recent Performance Analysis
  6.8.2 R&D Capabilities
  6.8.3 In Vitro Diagnostics
    6.8.3.1 Myriad RBM
  6.8.4 M&A Activity and Recent Partnerships
    6.8.4.1 Agreement with BioMarin Pharmaceutical
    6.8.4.2 Acquisition of Myriad RBM
    6.8.4.3 Strategic Debt Investment in Crescendo Bioscience
    6.8.4.4 Agreement with Cephalon
    6.8.4.5 Agreement with PharmaMar
6.9 QIAGEN
  6.9.1 Sales and Recent Performance Analysis
  6.9.2 Continued Expansion in the Emerging Markets
  6.9.3 R&D Capabilities
    6.9.3.1 More than 15 Projects to Co-Develop and Market Diagnostic Products
    6.9.3.2 Provider of Choice for Molecular Diagnostic Tools
  6.9.4 Recent M&A Activity and Other Developments
    6.9.4.1 Acquisition of Cellestis Ltd.
    6.9.4.2 Acquisition of Ipsogen
    6.9.4.3 Partnership with Pfizer
    6.9.4.4 Partnership with Eli Lilly
    6.9.4.5 Acquisition of SABiosciences Corporation
    6.9.4.6 Acquisition of DxS Ltd (Now QIAGEN Manchester)
    6.9.4.7 Acquisition of Explera s.r.l
6.10 In Vitro Diagnostics Sector Fast Becoming Crowded

7. CONCLUSIONS

7.1 In Vitro Diagnostics: An Attractive Segment of the Healthcare Market
7.2 Big Pharma Dominated the IVD Market in 2011
7.3 The Rise of Generic Medical Devices
7.4 What Will Succeed in the IVD Market?
7.5 Small Companies Can Have a Big Impact on the Industry and Market to 2023

List Of Tables

LIST OF TABLES

Table 2.1 IVD Revenues ($bn) and Market Shares (%) by Class, 2011-2012
Table 2.2 Advantages and Disadvantages of POC Diagnostics
Table 2.3 Genetic In Vitro Diagnostic Tests Available, 2012
Table 2.4 IVD Tests: Overall World Market and Submarket Revenue ($bn) Forecasts, 2011, 2012, 2018 and 2023
Table 2.5 Leading Manufacturers: IVD Revenue as a Share (%) of Total Revenue, 2011
Table 2.6 Leading Companies in the IVD Market: Net Sales ($bn) and Market Shares (%), 2011
Table 3.1 Danaher: Key Facts, 2013
Table 3.2 Danaher: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2011
Table 3.3 Danaher: Life Sciences & Diagnostics Revenue ($bn), 2009-2011
Table 3.4 Danaher: IVD Revenue ($bn) Forecast, 2012-2023
Table 3.5 Abbott: Key Facts, 2013
Table 3.6 Abbott: Net Sales ($bn) and Revenue Shares (%) by Business Segment, 2011
Table 3.7 Abbott: Revenues ($bn) and Revenue Shares (%) by Geographical Region, 2011
Table 3.8 Abbott Diagnostics: Revenues ($bn) and Revenue Shares (%) by Sub-Segment, 2011
Table 3.9 Abbott: Diagnostics Revenue ($bn), 2009-2011
Table 3.10 Abbott: IVD Revenue ($bn) Forecast, 2012-2023
Table 3.11 Johnson & Johnson: Key Facts, 2013
Table 3.12 Johnson & Johnson: Revenues ($bn) and Revenue Shares (%) by Business Segment, 2011
Table 3.13 Johnson & Johnson: Revenues ($bn) and Revenue Shares (%) by Region, 2011
Table 3.14 J&J Medical Devices and Diagnostics: Revenue ($bn) and Revenue Shares (%) by Brand, 2011
Table 3.15 J&J Medical Devices and Diagnostics: Revenue ($bn) and Revenue Shares (%) by Region, 2011
Table 3.16 Johnson & Johnson: IVD Revenue ($bn) Forecast, 2012-2023
Table 3.17 Bio-Rad: Key Facts, 2013
Table 3.18 Bio-Rad: Clinical Diagnostics Revenue ($bn), 2009-2011
Table 3.19 Bio-Rad: IVD Revenue Forecast ($bn), 2012-2023
Table 3.20 BD: Key Facts, 2013
Table 3.21 Becton Dickinson: Net Sales ($bn) and Revenue Shares (%) by Sector, 2011
Table 3.22 BD: Company Revenue ($bn), 2006-2011
Table 3.23 BD: IVD Revenue Forecast ($bn), 2012-2023
Table 3.24 Thermo Fisher: Key Facts, 2013
Table 3.25 Thermo Fisher: Net Sales ($bn), 2007-2011
Table 3.26 Thermo Fisher: Net Sales ($bn) and Revenue Shares (%) by Sector, 2011
Table 3.27 Thermo Fisher: Life Sciences & Diagnostics Revenue ($bn), 2009-2011
Table 3.28 Thermo Fisher: IVD Revenue ($bn) Forecast, 2012-2023
Table 4.1 Roche: Key Facts, 2013
Table 4.2 Roche: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
Table 4.3 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Region, 2011
Table 4.4 Roche Diagnostics: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
Table 4.5 Roche Diagnostics: Key Diagnostic Products Recently Launched
Table 4.6 Roche Diagnostics: Marketed Diagnostic Products, 2013
Table 4.7 Roche Diagnostics: Selected Products with an In-house Companion Diagnostic Drug Programme
Table 4.8 Roche: IVD Revenue ($bn) Forecast, 2012-2023
Table 4.9 Siemens: Key Facts, 2013
Table 4.10 Siemens: Revenues ($bn) and Revenue Shares (%) by Sector, 2011
Table 4.11 Siemens: Revenue ($bn) and Revenue Shares (%) by Region, 2011
Table 4.12 Siemens Healthcare: Revenue ($bn) and Revenue Shares (%) by Region, 2011
Table 4.13 Siemens Diagnostics: Ranking by Sector, 2011
Table 4.14 Siemens: IVD Revenue ($bn) Forecast, 2012-2023
Table 4.15 bioMйrieux: Key Facts, 2013
Table 4.16 bioMйrieux: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
Table 4.17 bioMйrieux: Clinical Applications Revenue ($m) and Revenue Shares (%) by Sector, 2011
Table 4.18 bioMйrieux: IVD Revenue ($bn) Forecast, 2012-2023
Table 5.1 Sysmex: Key Facts, 2013
Table 5.2 Sysmex: Revenue ($m) by Sector, 2007-2011
Table 5.3 Sysmex: IVD Revenue ($bn) Forecast, 2012-2023
Table 5.4 Arkray: Key Facts, 2013
Table 5.5 Arkray: IVD Revenue ($bn) Forecast, 2012-2023
Table 6.1 Dako: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
Table 6.2 Dako: Revenues ($bn) and Revenue Shares (%) by Region, 2011
Table 6.3 Dako: Marketed Diagnostic Products, 2013
Table 6.4 Genomic Health: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2011
Table 6.5 Genomic Health: R&D Expense ($m) and R&D Expense as a Percentage of Sales (%), 2011
Table 6.6 LabCorp: Revenues ($bn) and Revenue Shares (%) by Reporting Segment, 2011
Table 6.7 Selected List of LabCorp's Menu of Diagnostic Products, 2013
Table 6.8 LabCorp: Recently Launched Diagnostic Products, 2012
Table 6.9 Life Technologies: Revenue ($bn) and Revenue Shares (%) by Sector, 2011
Table 6.10 MDxHealth: Revenue ($m) and Revenue Shares (%) by Reporting Segment, 2011
Table 6.11 MDxHealth: In Vitro Diagnostics Pipeline, 2013
Table 6.12 Myriad: Revenue ($m) and Revenue Shares (%) by Sector, 2011
Table 6.13 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Product, 2011
Table 6.14 Myriad Molecular Diagnostics: Revenue ($m) and Revenue Shares (%) by Sector, 2011
Table 6.15 Myriad: Biomarker Product Portfolio, 2012
Table 6.16 Myriad: Diagnostic Products, 2013
Table 6.17 QIAGEN: Revenue ($m) and Revenue Shares (%) by Customer Class, 2011
Table 6.18 QIAGEN: Revenue ($m) and Revenue Shares (%) by Region, 2011
Table 6.19 QIAGEN: Selected Co-development Projects in the Pipeline, 2013
Table 6.20 QIAGEN: Marketed Diagnostic Products, 2013
Table 6.21 QIAGEN: Recent M&A Activity
Table 6.22 Other Companies Operating in the IVD Market, 2013
Table 7.1 Leading IVD Manufacturers by Company Type, 2011

About

IVD Revenue Forecast, 2013-2023 In 2011, BD’s total diagnostics revenues increased by 7.0% over fiscal year 2010 to reach $2.5bn. The diagnostic systems accounted for $1.2bn in revenues whereas the preanalytical systems(which include products such as evacuated tubes, multi-sample needles, capillary devices and urine collection, transfer and transport devices marketed under BD Vacutainer Brand) contributed $1.3bn in revenues. The company reported strong growth in both the Women’s Health and Cancer, and the Infectious Disease product offerings within the Diagnostic Systems unit as well as growth of safety-engineered products in its preanalytical systems in this segment. 

Throughout the forecast period, BD’s IVD revenue (excluding preanalytical systems) will increase, although strong competition from other market leaders in this sector will affect many of its products in that period. By 2017, BD’s diagnostic revenue will have reached $1.6bn (Table 3.23 and Figure 3.32).

Beyond the middle of our forecast period, BD may be able to increase the rate of revenue growth through the launch of new products. BD’s pipeline continues to mature and the company reported launching of 10 new products in 2012 including ones in the diagnostic sector. BD also reported its acquisitions have added about 100 basis points to its growth as the company continued to experience strong acceptance of products for molecular testing systems for infectious diseases and women’s health in the markets. The company also has strong R&D investments with more resources directed away from line extensions and toward programmes that it believes will have a greater impact on improving patient outcomes and the efficiency of healthcare. In 2012, BD’sdiagnostic systems unit launched the BD MAX System, a cost effective and fully automated, bench-top molecular system designed to perform a broad range of molecular tests, and the BD FACSVerse Flow Cytometer, a scalable system that can analyze and support a wide range of research applications.

As well as these products, if BD’s pipeline products and services are launched around the middle of the period and achieve steady uptake, revenue from these diagnostic products could further establish the company’s position as one of the leaders in that industry. 

BD also intends to increase its presence in the emerging markets and strengthen its revenue stream from these markets. In 2011, it enjoyed strong growth in these markets reaching 23% of company sales, fuelled by BD’s second year of increased investment. BD’s latest information indicates sales in China have grown by ~24.8% in 2012.